用可编程阿尔茨海默病治疗的粉样β调节基因电路
Madeline R Spetz1, Hyosung Kim2, Daniel Chavarria2
1Department of Biomedical Engineering, Vanderbilt University, Nashville, TN.
bioRxiv : the preprint server for biology
|March 31, 2025
概括
研究人员设计了一种用于阿尔茨海默病 (AD) 的新型细胞疗法,使用星体细胞上的合成Notch受体准粉样β (Aβ). 这种方法旨在通过重编程脑细胞来缓解AD中的神经炎症和神经元损失.
科学领域:
- 神经科学是一个神经科学.
- 生物技术是生物技术.
- 细胞疗法细胞疗法
背景情况:
- 阿尔茨海默病 (AD) 涉及粉样β (Aβ) 积累,目前的抗体疗法显示有争议的疗效和副作用.
- 中枢神经系统细胞,特别是星球细胞,在阿尔茨海默病中变得功能障碍,并导致神经退行.
研究的目的:
- 开发一种用于AD的工程细胞疗法,使用合成Notch (synNotch) 受体来编程星球细胞.
- 创建Aβ敏感的synNotch受体,能够识别并响应大脑中的粉样β.
主要方法:
- 使用临床测试的抗Aβ单克隆抗体 (mAbs) 构建了synNotch受体.
- 在星球细胞中表达了synNotch受体,使它们能够在Aβ检测时对治疗性转基因进行上调.
- 在试验室和AD的5xFAD小鼠模型中测试了工程天体细胞.
主要成果:
- 工程天体细胞识别了合成Aβ42和Aβ40,具有不同的灵敏度.
- 在对Aβ的反应中,SynNotch天体细胞调节了像大脑衍生的神经营养因子和细胞因子对手等转基因.
- 工程细胞部分减弱了反应性天体细胞表型,并促进了内皮屏障特性.
- 在5xFAD小鼠大脑中的工程细胞中显示出强大的Aβ诱导的转基因表达.
结论:
- Aβ-synNotch受体是开发有针对性的基于细胞的AD疗法的有希望的工具.
- 这种方法提供了一种重编程神经退行性的策略,缓解质反应和神经元损失.
- 工程细胞疗法具有积极影响AD病理环境的潜力.
更多相关视频
08:01Intracerebroventricular Injection of Amyloid-β Peptides in Normal Mice to Acutely Induce Alzheimer-like Cognitive Deficits
Published on: March 16, 2016
41.9K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.2K
相关概念视频
01:26Alzheimer's Disease: Overview
350
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
350
01:22Alzheimer's Disease: Treatment
133
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
133
03:03Amyloid Fibrils
9.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.1K